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Abstract
Readers in immunology are familiar with the importance of antigen presenting cells in mounting
immune responses. For the purpose of this particular editorial article, however, the abbreviation
APC will stand for article processing charges. The publisher will introduce APCs for this Journal in
May, 2005. Here we explain why article-processing charges are important to maintain our Open
Access journal.
Journal of Autoimmune Diseases is published by BioMed
Central, an independent publisher committed to ensuring
peer-reviewed biomedical research is Open Access – uni-
versally and freely available online to everyone, with
authors retaining copyright, and the full text being
archived in numerous internationally recognised free
repositories [1]. Journal of Autoimmune Diseases however,
has taken this further, by making all  its content Open
Access. To fund this, authors of articles accepted for pub-
lication in the Journal  will be asked to pay an article-
processing charge (APC). In 2005, that charge will be 330
GBP.
Traditionally, readers pay to access articles, either through
subscriptions or by paying a fee each time they download
an article. Escalating journal subscription prices have
resulted in libraries subscribing to fewer journals [2], and
the range of articles available to readers is therefore lim-
ited. Although traditional journals publish authors' work
for free (unless there are page or colour charges), having
to pay to access articles limits how many can read, use and
cite them.
Journal of Autoimmune Diseases' Open Access policy
changes the way in which articles are published. First, all
articles become freely and universally accessible online,
and so an author's work can be read by anyone at no cost.
Second, the authors hold copyright for their work and
grant anyone the right to reproduce and disseminate the
article, provided that it is correctly cited and no errors are
introduced [1]. Third, a copy of the full text of each article
is permanently archived in a number of online repositor-
ies separate from the journal. Articles published in Journal
of Autoimmune Diseases are archived in PubMed Central
[3], the US National Library of Medicine's full-text repos-
itory of life science literature, and also in repositories at
the University of Potsdam [4] in Germany, at INIST [5] in
France and in e-Depot [6], the National Library of the
Netherlands' digital archive of all electronic publications.
Who benefits from the Open Access?
Open Access has four broad benefits for science and the
general public. First, authors are assured that their work is
disseminated to the widest possible audience, given that
there are no barriers to access their work. It has been
shown that free online articles are more highly cited
because of their easier availability [7]. Second, the infor-
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mation available to researchers will not be limited by
what their library can afford, and the widespread availa-
bility of articles will enhance literature searching [8].
Third, the results of publicly funded research will be acces-
sible to all taxpayers and not just those with access to a
library with a subscription. Note that this public accessi-
bility may become a legal requirement in the USA if the
proposed Public Access to Science Act is made law [9].
Fourth, a country's economy will not influence its scien-
tists' ability to access articles because resource-poor coun-
tries (and institutions) will be able to read the same
material as wealthier ones (although creating access to the
internet is another matter [10]). APC will allow continued
Open Access to all of the articles published in Journal of
Autoimmune Diseases.
What does APC cover?
The APC pays for the article to be freely and universally
accessible in various formats online, and for the processes
required for inclusion in PubMed and archiving in
PubMed Central, e-Depot, Potsdam and INIST. Although
some authors may consider 330 GBP expensive, it must be
remembered that Journal of Autoimmune Diseases does not
levy additional page or colour charges on top of this fee,
which can easily exceed 330 GBP. With the article being
online only, any number of colour figures and photo-
graphs can be included, at no extra cost.
How will it work?
Authors will be asked to pay 330 GBP if their article is
accepted for publication. Waiver requests will be consid-
ered on a case-by-case basis, by the Editor-in-Chief.
Authors can circumvent the charge by getting their institu-
tion to become a 'member' of BioMed Central, whereby
the annual membership fee covers the APC for all authors
at that institution for that year. Current members include
NHS England, the World Health Organization, the US
National Institutes of Health, Harvard, Princeton and Yale
universities, and all UK universities [11]. No charge will
be made for articles that are rejected after peer review.
By providing a forum for Open Access, APC will enable
Journal of Autoimmune Diseases to better serve the scientific
community. We believe this change will benefit our read-
ers and aid research in the field of autoimmunity.
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